Silymarin effect on amyloid-β plaque accumulation and gene expression of APP in an Alzheimer's disease rat model

DARU, Journal of Pharmaceutical Sciences

Volumn 22, Issue 1, 2014, Pages

  Yaghmaei, Parichehreh ^a   Azarfar, Katia ^a   Dezfulian, Mehrooz ^b   Ebrahim Habibi, Azadeh ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; Beta amyloid; Passive avoidance learning; RT PCR; Silymarin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; SILYMARIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HIPPOCAMPUS; HISTOPATHOLOGY; LATENT PERIOD; MALE; MEMORY DISORDER; NONHUMAN; PASSIVE AVOIDANCE; PASSIVE AVOIDANCE TEST; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84893360309     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-22-24     Document Type: Article

References (52)

1. Alzheimer's disease. Blennow K, de Leon MJ, Zetterberg H, Lancet 2006 368 9533 387 403 10.1016/S0140-6736(06)69113-7 16876668 (Pubitemid 44108123)
2. Deciphering the molecular basis of memory failure in Alzheimer's disease. Walsh DM, Selkoe DJ, Neuron 2004 44 1 181 193 10.1016/j.neuron.2004.09.010 15450169 (Pubitemid 39348839)
3. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Butterfield DA, Reed T, Newman SF, Sultana R, Free Radic Biol Med 2007 43 5 658 677 10.1016/j.freeradbiomed.2007.05.037 17664130 (Pubitemid 47102132)
4. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. Farfara D, Lifshitz V, Frenkel D, J Cell Mol Med 2008 12 3 762 780 10.1111/j.1582-4934.2008.00314.x 18363841 (Pubitemid 351718063)
5. Beta-amyloid stimulation of microglia and monocytes results in TNF alpha dependent expression of inducible nitric oxide synthase and neuronal apoptosis. Combs CK, Karlo JC, Kao S-C, Landreth GE, J Neurosci 2001 21 4 1179 1188 11160388 (Pubitemid 32128763)
6. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K, Neurodegener Dis 2009 6 3 87 94 10.1159/000203774 19229112
7. Novel a isoforms in Alzheimers disease-their role in diagnosis and treatment. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H, Curr Pharm Des 2011 17 25 2594 2602 10.2174/138161211797416039 21728980
8. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM, Alzheimers Dement 2013 9 5 481 487 10.1016/j.jalz.2012.08.004 23232269
9. Effects of injected Alzheimer beta-amyloid cores in rat brain. Frautschy SA, Baird A, Cole GM, Proc Natl Acad Sci U S A 1991 88 19 8362 8366 10.1073/pnas.88.19.8362 1924295 (Pubitemid 21915356)
10. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Maurice T, Lockhart BP, Privat A, Brain Res 1996 706 2 181 193 10.1016/0006-8993(95)01032-7 8822355 (Pubitemid 26048681)
11. Analysis of the active components of silymarin. Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J, J Chromatogr A 2003 990 1-2 239 245 12685603 (Pubitemid 36293880)
12. Silybin and silymarin-new effects and applications. Kren V, Walterova D, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005 149 1 29 41 10.5507/bp.2005.002 16170386
13. Protective effects of the flavonoid mixture, silymarin, on fetal rat brain and liver. la Grange L, Wang M, Watkins R, Ortiz D, Sanchez ME, Konst J, Lee C, Reyes E, J Ethnopharmacol 1999 65 1 53 61 10.1016/S0378-8741(98)00144-5 10350368 (Pubitemid 29193063)
14. Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice. Lu P, Mamiya T, Lu LL, Mouri A, Zou LB, Nagai T, Hiramatsu M, Ikejima T, Nabeshima T, Br J Pharmacol 2009 157 7 1270 1277 10.1111/j.1476-5381.2009.00295.x 19552690
15. The effect of intrahippocampal beta amyloid (1-42) peptide injection on oxidant and antioxidant status in rat brain. Cetin F, Dincer S, Ann N Y Acad Sci 2007 1100 510 517 10.1196/annals.1395.056 17460216 (Pubitemid 47092690)
16. Paxinos G, Watson C, The rat brain in stereotaxic coordinates: hard cover edition The Netherlands: Academic Press, Elsevier 2006
17. Prolonged ethanol consumption influences shuttle box and passive avoidance performance in rats. Guaza C, Borrell J, Physiol Behav 1985 34 2 163 165 10.1016/0031-9384(85)90099-X 4001180 (Pubitemid 15135421)
18. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. Gandy S, J Clin Invest 2005 115 5 1121 1129 15864339 (Pubitemid 40629026)
19. Silymarin attenuated the amyloid beta plaque burden and improved behavioral abnormalities in an Alzheimer's disease mouse model. Murata N, Murakami K, Ozawa Y, Kinoshita N, Irie K, Shirasawa T, Shimizu T, Biosci Biotechnol Biochem 2010 74 11 2299 2306 10.1271/bbb.100524 21071836
20. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. Boller F, Forette F, Biomed Pharmacother 1989 43 7 487 491 10.1016/0753-3322(89)90109-1 2684292 (Pubitemid 19266394)
21. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Robbins T, McAlonan G, Muir J, Everitt B, Behav Brain Res 1997 83 1 15 23 9062655 (Pubitemid 27086609)
22. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta protein. Selkoe DJ, Ann N Y Acad Sci 2000 924 1 17 25 11193794 (Pubitemid 32050177)
23. Cholinesterase inhibitors used in the treatment of Alzheimer's disease. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J, Drugs Aging 2004 21 7 453 478 10.2165/00002512-200421070-00004 15132713 (Pubitemid 38736890)
24. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Cheng B, Gong H, Xiao H, Petersen RB, Zheng L, Huang K, Biochimica et Biophysica Acta (BBA)-General Subjects 2013 1830 10 4860 4871 10.1016/j.bbagen.2013.06.029
25. Beta-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge. Citron M, Trends Pharmacol Sci 2004 25 2 92 97 10.1016/j.tips.2003.12.004 15102495 (Pubitemid 38183395)
26. Multi-Target-Directed ligands in Alzheimer's disease treatment. Bajda M, Guzior N, Ignasik M, Malawska B, Curr Med Chem 2011 18 32 4949 4975 10.2174/092986711797535245 22050745
27. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW, J Neurochem 1995 64 1 253 265 7798921
28. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. Kubo T, Nishimura S, Kumagae Y, Kaneko I, J Neurosci Res 2002 70 3 474 483 10.1002/jnr.10391 12391608 (Pubitemid 35222384)
29. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T, Behav Brain Res 2007 180 2 139 145 10.1016/j.bbr.2007.03. 001 17420060 (Pubitemid 46719420)
30. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T, Behav Brain Res 2008 190 2 224 232 10.1016/j.bbr.2008.03.002 18420288
31. Critical role of soluble amyloid beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A, Proc Natl Acad Sci 2012 109 22 8740 8745 10.1073/pnas.1206171109 22592800
32. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Arch Neurol 2011 68 8 1040 10.1001/archneurol.2011.167 21825241
33. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: a behavioral, biochemical and immunohistological study in Wistar rats. Raza SS, Khan MM, Ashafaq M, Ahmad A, Khuwaja G, Khan A, Siddiqui MS, Safhi MM, Islam F, J Neurol Sci 2011 309 1 45 54 21840019
34. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Galhardi F, Mesquita K, Monserrat JM, Barros DM, Food Chem Toxicol 2009 47 10 2655 2660 10.1016/j.fct.2009.07.030 19647779
35. Protective effect of silymarin on oxidative stress in rat brain. Nencini C, Giorgi G, Micheli L, Phytomedicine 2007 14 2 129 135 16638633 (Pubitemid 46136941)
36. Neuroprotective effect of silibinin in diabetic mice. Marrazzo G, Bosco P, la Delia F, Scapagnini G, di Giacomo C, Malaguarnera M, Galvano F, Nicolosi A, Li Volti G, Neurosci Lett 2011 504 3 252 256 10.1016/j.neulet.2011.09.041 21970972
37. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Lu P, Mamiya T, Lu L, Mouri A, Niwa M, Kim HC, Zou LB, Nagai T, Yamada K, Ikejima T, et al. Behav Brain Res 2010 207 2 387 393 10.1016/j.bbr.2009.10.024 19857526
38. Silibinin: a novel inhibitor of Abeta aggregation. Yin F, Liu J, Ji X, Wang Y, Zidichouski J, Zhang J, Neurochem Int 2011 58 3 399 403 10.1016/j.neuint.2010.12.017 21185897
39. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Cheng B, Gong H, Li X, Sun Y, Zhang X, Chen H, Liu X, Zheng L, Huang K, Biochem Biophys Res Commun 2012 419 3 495 499 10.1016/j.bbrc.2012.02. 042 22366091
40. Amyloid formation and inhibition of an all-beta protein: a study on fungal polygalacturonase. Chinisaz M, Ghasemi A, Larijani B, Ebrahim-Habibi A, J Mol Struct 2014 1059 94 100
41. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M, J Neurochem 2003 87 1 172 181 10.1046/j.1471-4159.2003.01976.x 12969264 (Pubitemid 37210651)
42. The green tea polyphenol (-)-epigallocatechin gallate attenuates β-amyloid-induced neurotoxicity in cultured hippocampal neurons. Choi Y-T, Jung C-H, Lee S-R, Bae J-H, Baek W-K, Suh M-H, Park J, Park C-W, Suh S-I, Life Sci 2001 70 5 603 614 10.1016/S0024-3205(01)01438-2 11811904 (Pubitemid 34082702)
43. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, J Med Chem 2005 48 5 1576 1587 10.1021/jm049274d 15743199
44. Curcumin binds to the -helical intermediate and to the amyloid form of prion protein-a new mechanism for the inhibition of PrPSc accumulation. Hafner-Bratkovič I, Gašperšič J, Šmid LM, Bresjanac M, Jerala R, J Neurochem 2008 104 6 1553 1564 10.1111/j.1471-4159. 2007.05105.x 17996023 (Pubitemid 351316769)
45. Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of β-amyloid peptide. Liu D, Xu Y, Feng Y, Liu H, Shen X, Chen K, Ma J, Jiang H, Biochemistry 2006 45 36 10963 10972 10.1021/bi060955f 16953582 (Pubitemid 44360166)
46. Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system. Youdim KA, Shukitt-Hale B, Joseph JA, Free Radic Biol Med 2004 37 11 1683 1693 10.1016/j.freeradbiomed.2004.08.002 15528027 (Pubitemid 39441053)
47. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Baluchnejadmojarada T, Roghanib M, Mafakheria M, Neurosci Lett 2010 480 3 206 210 10.1016/j.neulet.2010.06.038 20600617
48. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA, Am J Med 2002 113 6 506 515 10.1016/S0002-9343(02)01244-5 12427501 (Pubitemid 35335804)
49. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Feher J, Lengyel G, Curr Pharm Biotechnol 2012 13 1 210 217 10.2174/138920112798868818 21466434
50. Gene expression profiling in fetal, aged, and alzheimer hippocampus: a continuum of stress-related signaling. Lukiw WJ, Neurochem Res 2004 29 6 1287 1297 15176485 (Pubitemid 39023501)
51. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, de Pooter T, van Duijn CM, de Deyn PP, van Broeckhoven C, Am J Hum Genet 2006 78 6 936 946 10.1086/504044 16685645 (Pubitemid 43787686)
52. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP? Howlett DR, Richardson JC, Histol Histopathol 2009 24 1 83 100 19012248